论文部分内容阅读
目的探讨吡柔比星(THP)膀胱灌注化疗预防浅表性膀胱癌术后复发的预期疗效和安全性。方法对54例浅表性膀胱癌术后患者应用THP(40mg)膀胱灌注,每周1次,共8次;以后每月1次,共8次。结果随访24个月￣36个月,全组无肿瘤复发率为85.2%,复发率为14.8%,28例出现局部症状,除1例出现高热外,其余患者均未出现明显全身性症状。结论THP用于膀胱灌注预防浅表性膀胱癌术后复发有满意疗效,体内应用安全性好,值得推广。
Objective To investigate the efficacy and safety of intravesical chemotherapy with pirarubicin (THP) in preventing postoperative recurrence of superficial bladder cancer. Methods 54 patients with superficial bladder cancer were treated with THP (40mg) bladder perfusion once a week for a total of 8 times; then once a month for a total of 8 times. Results After 24 months to 36 months follow-up, the overall tumor-free recurrence rate was 85.2%, and the recurrence rate was 14.8%. 28 patients developed local symptoms. Except one patient developed hyperthermia, none of the other patients had obvious systemic symptoms. Conclusion THP is effective for the prevention of postoperative recurrence of superficial bladder cancer by intravesical instillation. It has good safety in vivo and is worthy of promotion.